Precigen Inc (PGEN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.63B
Last updated: Nov 17, 2026 at 11:06 AM ET
Precigen Inc (PGEN) Competitors
The companies most similar to Precigen are Ultragenyx (RARE), UroGen Pharma (URGN) and Replimune Group (REPL). By market cap, Precigen ranks 9th of the 13 companies on this page; Cogent Biosciences (COGT) is the largest at $4.97B.
Peer Comparison
PGEN's ROIC of 18.9% is above the peer median of -57.9%, and its revenue growth of 2438.0% is above the median of 24.3%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Precigen (PGEN) | $1.63B | 98.6x | 9.9x | 15.5% | 18.9% | 2438.0% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| UroGen Pharma Ltd (URGN) | $1.28B | N/A | 5.7x | -26.3% | -73.7% | 223.9% | 0.00% |
| Replimune Group Inc (REPL) | $2.08B | N/A | N/A | 0.0% | -65.4% | 0.0% | 0.00% |
| Intellia Therapeutics Inc (NTLA) | $1.36B | N/A | 26.1x | 0.0% | -50.0% | -48.0% | 0.00% |
| Prime Medicine, Inc. Common Stock (PRME) | $949.85M | N/A | 105.5x | 0.0% | N/A | 243.9% | 0.00% |
| Uniqure NV (QURE) | $1.67B | N/A | 75.8x | 0.0% | -57.9% | 40.4% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $1.90B | N/A | 168.0x | 0.0% | -104.3% | -100.0% | 0.00% |
| Xencor Inc (XNCR) | $2.78B | N/A | 13.5x | -58.8% | -17.3% | 454.9% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Cogent Biosciences Inc (COGT) | $4.97B | N/A | N/A | 0.0% | -43.4% | -100.0% | 0.00% |
| Vor Biopharma Inc (VOR) | $1.19B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $1.68B | 6.4x | 13.5x | 0.0% | -57.9% | 24.3% | 0.00% |
Similar Companies
These are the 12 companies most similar to Precigen, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| UroGen Pharma Ltd (URGN) | UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases... | URGN competitors |
| Replimune Group Inc (REPL) | Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts. | REPL competitors |
| Intellia Therapeutics Inc (NTLA) | Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts. | NTLA competitors |
| Prime Medicine, Inc. Common Stock (PRME) | Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology... | PRME competitors |
| Uniqure NV (QURE) | uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. | QURE competitors |
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based... | ZBIO competitors |
| Xencor Inc (XNCR) | Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed... | XNCR competitors |
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
| Cogent Biosciences Inc (COGT) | Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. | COGT competitors |
| Vor Biopharma Inc (VOR) | Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. | VOR competitors |
Frequently Asked Questions About PGEN
Who are Precigen's main competitors?
The companies most similar to Precigen include Ultragenyx (RARE), UroGen Pharma (URGN), Replimune Group (REPL), Intellia Therapeutics (NTLA) and Prime Medicine, Inc. Common Stock (PRME), listed from the closest match.
Who is Precigen's biggest competitor?
Cogent Biosciences (COGT) is the largest of the similar companies at $4.97B; Ultragenyx (RARE) is the closest match by business profile, size, sector and industry.
How does PGEN stock compare with its competitors?
PGEN's P/E is 98.6x against a peer median of 6.4x; its P/S is 9.9x against a peer median of 13.5x; its net margin is 15.5% against a peer median of 0.0%.
Which of Precigen's competitors pays a higher dividend?
Precigen pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Precigen bigger than its competitors?
No. Precigen is 9th by market cap among the 13 companies on this page; the largest is Cogent Biosciences (COGT) at $4.97B.
PGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors